KAZEEM OLAJIDE: Open Payments
NPI 1184110165 · NEWARK, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$288 in 15 payments from 5 companies in 2025. Trend: 2023 $140 · 2024 $220 · 2025 $288
Food & beverage: $288
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 4 | $90 |
| Teva Pharmaceuticals USA, Inc. | 5 | $90 |
| Alkermes, Inc. | 3 | $53 |
| E.R. Squibb & Sons, L.L.C. | 2 | $37 |
| ABBVIE INC. | 1 | $17 |
Products named: INGREZZA, AUSTEDO XR, COBENFY, ARISTADA, VIVITROL, VRAYLAR.
Industry payments across NJ — which companies pay providers there.
